The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.

Here's where Dr. David Eifrig says to move your money immediately.

Richard U. DeSchutter net worth and biography

Richard DeSchutter Biography and Net Worth

Director of Bausch Health Companies

Mr. De Schutter has served on the Board since January 2017. He is the owner of asset management firm L.B. Gemini, Inc., where he has served as President and director since 2000. He previously served as the Chairman and CEO of DuPont Pharmaceuticals Company from July 2000 until its acquisition by Bristol-Myers Squibb in October 2001. Mr. De Schutter was also a director and Chief Administrative Officer of Pharmacia Corporation, which was created through the merger of Monsanto Company and Pharmacia & Upjohn in 2000. Prior to this merger, he was a director, Vice Chairman and Chief Administrative Officer for Monsanto. From 1995 to 1999, he served as Chairman and CEO of G.D. Searle & Co., Monsanto’s wholly owned pharmaceutical subsidiary. Mr. De Schutter earned a Bachelor of Science degree and a Master of Science Degree in Chemical Engineering from the University of Arizona.

Mr. De Schutter has served as a director of AuVen Therapeutics since 2007, and as a director of Sermonix Pharmaceuticals Inc. since April 2019. He previously served as Chairman Incyte Corporation, from 2003 to 2015, and Durata Therapeutics, Inc., from 2012 to 2014. He served as a director of Smith & Nephew plc from 2001 to 2014, during which time he served as Lead Independent Director from 2011 to 2014.

What is Richard U. DeSchutter's net worth?: The estimated net worth of Richard U. DeSchutter is at least $2.76 million as of August 4th, 2021. Mr. DeSchutter owns 317,109 shares of Bausch Health Companies stock worth more than $2,762,019 as of April 26th. This net worth estimate does not reflect any other investments that Mr. DeSchutter may own. Learn More about Richard U. DeSchutter's net worth.
How do I contact Richard U. DeSchutter?: The corporate mailing address for Mr. DeSchutter and other Bausch Health Companies executives is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. Bausch Health Companies can also be reached via phone at (514) 744-6792 and via email at [email protected]. Learn More on Richard U. DeSchutter's contact information.
Has Richard U. DeSchutter been buying or selling shares of Bausch Health Companies?: Richard U. DeSchutter has not been actively trading shares of Bausch Health Companies during the last ninety days. Most recently, on Wednesday, August 4th, Schutter Richard U. De bought 10,000 shares of Bausch Health Companies stock. The stock was acquired at an average cost of $25.01 per share, with a total value of $250,100.00. Following the completion of the transaction, the director now directly owns 317,109 shares of the company's stock, valued at $7,930,896.09. Learn More on Richard U. DeSchutter's trading history.
Who are Bausch Health Companies' active insiders?: Bausch Health Companies' insider roster includes Christina Ackermann (EVP), Seana Carson (EVP), Richard DeSchutter (Director), Sam Eldessouky (CFO), Joseph Gordon (Insider), William Humphries (Insider), Steven Miller (Director), Robert Spurr (Insider), and Amy Wechsler (Director). Learn More on Bausch Health Companies' active insiders.
Are insiders buying or selling shares of Bausch Health Companies?: In the last year, insiders at the sold shares 3 times. They sold a total of 6,948 shares worth more than $57,302.63. The most recent insider tranaction occured on December, 5th when EVP Seana Carson sold 220 shares worth more than $1,623.60. Insiders at Bausch Health Companies own 8.1% of the company. Learn More about insider trades at Bausch Health Companies.
Information on this page was last updated on 12/5/2023.

Richard U. DeSchutter Insider Trading History at Bausch Health Companies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/4/2021	Buy	10,000	$25.01	$250,100.00	317,109
3/3/2020	Buy	5,000	$23.08	$115,400.00	279,250
9/13/2018	Buy	125,000	$23.96	$2,995,000.00
5/15/2018	Buy	10,000	$21.80	$218,000.00
5/15/2018	Buy	15,000	$21.83	$327,450.00
3/8/2018	Buy	10,000	$15.34	$153,400.00	106,062
8/21/2017	Buy	10,000	$14.33	$143,300.00	77,479
5/11/2017	Buy	20,000	$13.90	$278,000.00	70,572
3/15/2017	Buy	10,000	$10.80	$108,000.00	25,190

Richard U. DeSchutter Buying and Selling Activity at Bausch Health Companies

Bausch Health Companies Company Overview

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Today's Range

Now: $8.71

$8.57

$8.82

50 Day Range

MA: $9.30

$8.46

$10.61

2 Week Range

Now: $8.71

$5.57

$11.46

Volume

2,081,585 shs

Average Volume

2,783,454 shs

Market Capitalization

$3.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85

Move Your Money Before May 22

From Stansberry Research | Ad